• Something wrong with this record ?

Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective

JY. Teoh, AM. Kamat, PC. Black, P. Grivas, SF. Shariat, M. Babjuk

. 2022 ; 19 (5) : 280-294. [pub] 20220331

Language English Country Great Britain

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc22018643
E-resources Online Full text

NLK ProQuest Central from 2009-04-01 to 1 year ago
Health & Medicine (ProQuest) from 2009-04-01 to 1 year ago

Links

PubMed 35361927
DOI 10.1038/s41585-022-00578-1
Knihovny.cz E-resources

Non-muscle-invasive bladder cancer (NMIBC) is an early-stage cancer without invasion into the detrusor muscle layer. Transurethral resection of bladder tumour (TURBT) is a diagnostic and potentially curative procedure for NMIBC, but has some limitations, including difficulties in ascertaining complete tumour removal upon piecemeal resection and the possibility of tumour re-implantation after the procedure. The oncological control of NMIBC is far from satisfactory, with a 1-year recurrence rate of 15-61%, and a 5-year recurrence rate of 31-78%. Various recurrence mechanisms have been described for NMIBC, such as undetected tumours upon cystoscopy, incomplete resection during TURBT, tumour re-implantation after TURBT, drop metastasis from upper tract urothelial carcinoma and field change cancerization. Understanding the recurrence mechanisms from a clinical perspective has strong implications for the optimization of NMIBC oncological outcomes, as a cure for patients with NMIBC can only be achieved by tackling all possible recurrence mechanisms in a comprehensive manner.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018643
003      
CZ-PrNML
005      
20220804134928.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41585-022-00578-1 $2 doi
035    __
$a (PubMed)35361927
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Teoh, Jeremy Yuen-Chun $u S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. jeremyteoh@surgery.cuhk.edu.hk $u European Association of Urology-Young Academic Urologists (EAU-YAU) Urothelial Cancer Working Group, Amsterdam, Netherlands. jeremyteoh@surgery.cuhk.edu.hk $1 https://orcid.org/0000000293612342
245    10
$a Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective / $c JY. Teoh, AM. Kamat, PC. Black, P. Grivas, SF. Shariat, M. Babjuk
520    9_
$a Non-muscle-invasive bladder cancer (NMIBC) is an early-stage cancer without invasion into the detrusor muscle layer. Transurethral resection of bladder tumour (TURBT) is a diagnostic and potentially curative procedure for NMIBC, but has some limitations, including difficulties in ascertaining complete tumour removal upon piecemeal resection and the possibility of tumour re-implantation after the procedure. The oncological control of NMIBC is far from satisfactory, with a 1-year recurrence rate of 15-61%, and a 5-year recurrence rate of 31-78%. Various recurrence mechanisms have been described for NMIBC, such as undetected tumours upon cystoscopy, incomplete resection during TURBT, tumour re-implantation after TURBT, drop metastasis from upper tract urothelial carcinoma and field change cancerization. Understanding the recurrence mechanisms from a clinical perspective has strong implications for the optimization of NMIBC oncological outcomes, as a cure for patients with NMIBC can only be achieved by tackling all possible recurrence mechanisms in a comprehensive manner.
650    12
$a karcinom z přechodných buněk $x patologie $x chirurgie $7 D002295
650    _2
$a cystektomie $x metody $7 D015653
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a invazivní růst nádoru $7 D009361
650    _2
$a lokální recidiva nádoru $x chirurgie $7 D009364
650    12
$a nádory močového měchýře $x diagnóza $x chirurgie $7 D001749
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Kamat, Ashish M $u The University of Texas MD Anderson Cancer Center, Houston, TX, USA $1 https://orcid.org/0000000335469928
700    1_
$a Black, Peter C $u Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
700    1_
$a Grivas, Petros $u Division of Oncology, Department of Medicine, University of Washington, Washington, USA $u Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, USA
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, Weill Cornell Medical College, New York, NY, USA $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia $u Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan $u Department of Urology, 2nd Faculty of Medicine, Hospital Motol, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000266276179
700    1_
$a Babjuk, Marek $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, 2nd Faculty of Medicine, Hospital Motol, Charles University, Prague, Czech Republic
773    0_
$w MED00184385 $t Nature reviews. Urology $x 1759-4820 $g Roč. 19, č. 5 (2022), s. 280-294
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35361927 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134922 $b ABA008
999    __
$a ok $b bmc $g 1822317 $s 1169886
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 19 $c 5 $d 280-294 $e 20220331 $i 1759-4820 $m Nature reviews. Urology $n Nat Rev Urol $x MED00184385
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Archiving options